India, April 1 -- GRI Bio, Inc. (GRI) Tuesday has priced its public offering at $3.60 per share, including Series Warrants, aiming to raise approximately $5 million before fees.
The offering includes 1,388,888 shares of common stock, with warrants exercisable at $3.20 per share. If fully exercised, the Series Warrants could generate an additional $13.3 million, though there is no guarantee of exercise. The offering is expected to close around April 2, 2025, subject to standard conditions, with H.C. Wainwright & Co. acting as the exclusive placement agent.
Proceeds will fund product development, working capital, and corporate expenses. The company's lead program, GRI-0621, targets idiopathic pulmonary fibrosis, with additional research int...